As 2022 comes to a close, we review Big Molecule Watch’s top five biosimilar regulatory developments of the year...more
1/3/2023
/ America Invents Act ,
Biden Administration ,
Biosimilars ,
China ,
Drug Pricing ,
EU ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Governor Newsom ,
Interchangeability ,
Life Sciences ,
Orange Book ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Purple Book ,
USPTO
On Friday, December 16, 2022, Regeneron moved to dismiss Mylan’s inequitable conduct defense and counterclaim against two of the six patents asserted in the parties’ BPCIA suit concerning Mylan’s proposed biosimilar to EYLEA....more